L’Oreal Must Stop Selling Harmful Hair Relaxers, Women’s Group Says As Lawsuits Stack Up
Level Up, fighting for gender justice in the UK, says L’Oreal should reformulate or remove its hair relaxers from the market based on a US National Institutes of Health study indicating that frequent, long-term use of such products more than doubles risk of developing uterine cancer. Meanwhile the beauty giant is embroiled in numerous related lawsuits in federal courts around the US.
You may also be interested in...
US district judge Mary Rowland decided not to throw out the majority of plaintiffs’ claims against L’Oreal, Revlon, SoftSheen-Carson and other hair-relaxer marketers on 13 November. She says plaintiffs have sufficiently pleaded at this stage that defendants’ negligence resulted in their unknowingly using toxic chemical straightening products on their hair, leading to cancers or other injuries.
In her complaint against L’Oreal and other marketers of hair-smoothing products, plaintiff Jenny Mitchell, who was diagnosed with uterine cancer in August 2018, cites an NIH study published in October as “the first epidemiologic evidence of association between use of straightening products and uterine cancer.” She claims the defendants engaged in negligent or fraudulent practices in their marketing and sale of hair-straightening products that they knew posed dangers to users.
Over The Counter 1 March 2024: The Emerging Benefits Of ‘Beauty-From-Within,’ Featuring Kenvue’s Paul LaTerra
In this episode of Over the Counter, HBW Insight speaks to Paul LaTerra, Director, R&D, Global Hair and Scalp for Kenvue, a New Jersey-based consumer health company that markets skin care brands Neutrogena, Aveeno and Lubriderm. We discuss growth of the beauty-from-within supplements market, how the products complement topical skin care and hair formulas and the growing body of research demonstrating significant skin and hair health benefits.